New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI® (etanercept) and FLIXABI® (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8–11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
Additional data presented at the congress include results from Phase I and Phase III studies of SB5, an adalimumab biosimilar candidate referencing Humira®.v Results showed sustained and comparable efficacy, and comparable safety and immunogenicity profiles over 52 weeks in patients who transitioned from Humira to SB5 at Week 24, compared with patients who continued to receive the reference productvi and those who continued on SB5.
“Biologics have benefitted a large number of patients, effectively revolutionizing the treatment of rheumatic diseases. Biosimilars can help more patients gain access and benefit from biologic therapies, while providing cost savings to healthcare systems and supporting future healthcare innovation,” said Alpna Seth, Ph.D., Senior Vice President and Global Head of the Biosimilars Business Unit at Biogen. “The data presented by our partners Samsung Bioepis at EULAR reinforce the comparable safety and efficacy of our anti-TNF biosimilars portfolio in patients living with chronic inflammatory conditions, including rheumatoid arthritis.”
“The integration of biosimilars in routine clinical practice is a crucial step to help patients’ access disease modifying biologic therapies they can significantly benefit from,” said Professor John Isaacs, Director of the Institute of Cellular Medicine at Newcastle University and consultant rheumatologist at the Freeman Hospital. “Patient safety is of the utmost importance, and we are beginning to see a solid bank of data that, together with real-world evidence, will further establish the role of biosimilars.”
The posters presented at the Annual European Congress of Rheumatology (EULAR 2016) by Samsung Bioepis include:
- Emery P, et al. Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients With Rheumatoid Arthritis: Comparison Between Continuing SB4 and Switching From Etanercept Reference Product to SB4 [THU0150] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Smolen JS, et al. Comparable Safety and Immunogenicity and Sustained Efficacy After Transition to SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients With Rheumatoid Arthritis: Results of Phase III Transition Study [FRI0162] – Friday, June 10, 2016, 11.50am BST, Poster Area
- Choe J-Y, et al. Efficacy and Safety Analysis by Overall Anti-drug Antibody Results up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Infliximab Reference Product in Phase III study [THU0140] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Durez P, et al. The 54-week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, to Infliximab Reference Product in Patients with Rheumatoid Arthritis [THU0149] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Weinblatt M, et al. Sustained Efficacy and Comparable Safety and Immunogenicity After Transition to SB5 (an Adalimumab Biosimilar) vs Continuation of the Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III study [FRI0161] – Friday, June 10, 2016, 11.50am BST, Poster Area
- Kay J, et al. Secondary Efficacy Results up to Week 24 from a Phase III Study Comparing SB5 (an Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [THU0138] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- Genovese MC, et al. Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 From a Phase III Study Comparing SB5 (an Adalimumab Biosimilar) With Adalimumab Reference Product in Patients With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [THU0146] – Thursday, June 9, 2016, 11.45am BST, Poster Area
- A Phase I Pharmacokinetic Study Comparing Pre-Filled Pen and Pre-Filled Syringe of SB5, an Adalimumab Biosimilar in Healthy Subjects [Abstract only]
BENEPALI is an etanercept biosimilar to the reference product Enbrel®7. BENEPALI is approved in Europe for the treatment of adults with moderate to severe RA, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis. BENEPALI is currently available in five European countries, namely, the UK, Germany, Norway, Sweden and the Netherlands.
FLIXABI is an infliximab biosimilar to the reference product Remicade®8. FLIXABI is approved in Europe for the treatment of adults with RA, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis. FLIXABI can also be used in patients 6–17 years old with severe, active Crohn’s disease or severely active ulcerative colitis.
SB5 is an investigational treatment being developed as a biosimilar to the reference product Humira®.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies, and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.
Biogen Safe Harbor
This press release includes forward-looking statements, including statements about the potential benefits of our products and programs and expected timing of results from clinical trials. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "will," and other words and terms of similar meaning. You should not place undue reliance on these statements. Drug development and commercialization is a lengthy and complex process, which involves a high degree of risk. Factors that could cause actual results to differ materially from our current expectations include: the risk that unexpected concerns may arise from additional data or analysis, or regulatory authorities may require additional data or information or further studies, or may fail to approve, or refuse to approve, or may delay approval of our biosimilar drug candidates risks related to our dependence on third parties for the development and commercialization of biosimilars; risks of legal actions, regulatory scrutiny or other challenges to biosimilars; and the risks of other unexpected hurdles. For more detailed information on the risks and uncertainties associated with our drug development and commercialization activities, please review the Risk Factors section of our most recent annual or quarterly report filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations, and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
i Enbrel is a registered trademark of Wyeth LLC.
ii Emery P, et al. Long-term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison Between Continuing SB4 and Switching from Etanercept Reference Product to SB4. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data
iii Remicade is a registered trademark of Janssen Biotech, Inc.
iv Smolen JS, et al. Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (an Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data.
v Humira is a registered trademark of Abbvie Biotechnology Ltd.
vi Weinblatt M, et al. Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) vs Continuation of the Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Study. Poster presented at the European League Against Rheumatism (EULAR) Annual Congress, 9 June 2016, London UK. Samsung Bioepis data
BIOGEN US MEDIA CONTACT:
Jason Glashow, +1 781-464-3260
BIOGEN EU MEDIA CONTACT:
Shannon Altimari, +41 41 392 1677
BIOGEN INVESTOR CONTACT:
Mike Hencke, +1 781-464-2442
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
JustPremium Launches Rich Video Product Suite19.3.2018 08:00 | Pressemelding
Programmatic rich media and video ad marketplace, JustPremium, has today announced the launch of a new product suite, Rich Video. The new offering allows clients to build multiple rich video ad units with a single click using the advertisers existing assets. Using Rich Video allows advertisers to create an engaging advert, leading to higher engagement and interaction rates. Ultimately these formats help create a better user experience and a higher return on investment. JustPremium launches this product at a time when quality video inventory has never been more in demand, and brand-safe video inventory that advertisers require has never been in shorter supply. Rich Video allows publishers to build multiple creative ad units in minutes, enabling them to test different options and optimise their message to give the best performance. By utilising the assets that have already been created for Facebook, Adwords and YouTube, this process allows advertisers to supercharge their existing conten
GovSat-1 Satellite Goes Operational19.3.2018 07:40 | Pressemelding
GovSat-1 enters operational service today, to provide secure communications to governmental and institutional users. GovSat-1 is the first satellite of GovSat, a public private partnership between the Government of Luxembourg and the world-leading satellite operator SES. The satellite was launched into space on 31 January on board a flight-proven SpaceX Falcon 9 rocket from Cape Canaveral Air Force Station, and has since undergone extensive testing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005458/en/ GovSat-1 launch. (Photo: SpaceX) The multi-mission satellite is operated by GovSat from the Secure Mission Operations Centre in Luxembourg. The highly flexible and resilient GovSat-1 payload uses dedicated frequencies in X-band and military Ka-band. It enables an array of applications such as connectivity for theatres of operation, interconnection of institutional or defence sites, border control, Intelligence, Surve
Digi Communications N.V.: Announcement on the Convocation Date for the Company’s GSM Approving the 2017 Annual Report19.3.2018 07:34 | Pressemelding
The Company would like to inform its investors and the market that the Board of Directors anticipates that on Wednesday, 21 March 2018, it will convene the general shareholders meeting (the “GSM”) called to approve, among others, the 2017 Annual Report. On the same date, the Company will make public, among others, its 2017 Annual Report and the auditor’s report. In accordance with the provisions of the articles of association of the Company, the GSM is scheduled to take place on 2 May 2018. Therefore, we would like to inform you with respect to the update to the Company’s Financial Reporting Calendar for 2018, which is available on Digi’s website. For details, please access the Digi’s website: www.digi-communications.ro (Investor Relations Section). About Digi Communications NV Digi is the parent holding company of RCS & RDS, a leading provider of pay TV and telecommunications services in Romania and Hungary. In addition, RCS & RDS provides mobile services as an MVNO to the large Roman
Dai Nippon Printing Chooses Gemalto’s Biometric Facial Recognition Solution to Facilitate Mobile Banking Access in Japan19.3.2018 06:00 | Pressemelding
Gemalto, the world leader in digital security, today announced that it has been selected by Dai Nippon Printing (DNP), a financial solutions provider in Japan, to make mobile banking transactions easier to use. Leveraging Gemalto’s facial biometric authentication solution - Mobile Protector- DNP has started to offer facial recognition to secure access to its mobile banking apps. This enables banking customers to easily and quickly log on to mobile banking services upon successful facial authentication, providing a more convenient user experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180318005005/en/ Facial recognition for mobile banking authentication. (Photo: Gemalto) Gemalto’s 2017 eBanking Trends research found that 68 percent of banks plan to implement facial recognition over the next five years. 80 percent of surveyed consumers perceived biometrics to be more secure than the traditional username and password co
Gemalto Helps European Banks Build Business Opportunities from PSD219.3.2018 06:00 | Pressemelding
Gemalto, the world leader in digital security, believes that the implementation of PSD2 (Payment Services Directive 2) offers European banks a unique opportunity to deliver digital innovation, robust protection and seamless user experience that will be critical in a new era of open markets. The Regulatory Technical Standards (RTS) have just been published in the EU Official Journal, and detail the responsibilities and obligations of all banking and payment stakeholders concerning access to account, customer data protection, user convenience, and payment security. Gemalto believes that long term success will be built around solutions tailored to individual requirements, whilst drawing on products and services already proven to deliver the core principles of PSD2. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180318005025/en/ Solutions to help financial institutions for implementation of PSD2. Credit: istockphoto Adoption of t
ExThera Medical Announces Creation of European Subsidiary19.3.2018 05:23 | Pressemelding
ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary. Carla brings more than 30 years of experience in clinical research and the commercialization of new medical devices in the European market to ExThera Medical, where she will oversee the strategic direction for ExThera’s European operations. “The establishment of our European subsidiary is an exciting milestone as we prepare for commercialization,” said Robert Ward, President and CEO of ExThera Medical. “Carla has a distinguished track record in medical device development and commercialization, including overseeing clinical research, regulatory affairs, quality assurance, and operations. As CEO of her company, Meditech, she successfully supported the rapid clinical adoption of many new medical devices. Carla’s strategic leadership w